{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:20:50Z","timestamp":1790914850733,"version":"4.1.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["SPORE-P50CA100707, R01CA207237, P01CA155258"],"award-info":[{"award-number":["SPORE-P50CA100707, R01CA207237, P01CA155258"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The incorporation of novel agents and monoclonal antibody-based therapies into the treatment of multiple myeloma (MM) has significantly improved long-term patient survival. However, the disease is still largely incurable, with high-risk patients suffering shorter survival times, partly due to weakened immune systems. Bispecific molecules, including bispecific antibodies (BisAbs) and bispecific T-cell engagers (BiTEs), encourage immune cells to lyse MM cells by simultaneously binding antigens on MM cells and immune effector cells, bringing those cells into close proximity. BisAbs that target B-cell maturation antigen (BCMA) and GPRC5D have shown impressive clinical activity, and the results of early-phase clinical trials targeting FcRH5 in patients with relapsed\/refractory MM (RRMM) are also promising. Furthermore, the safety profile of these agents is favorable, including mainly low-grade cytokine release syndrome (CRS). These off-the-shelf bispecific molecules will likely become an essential part of the MM treatment paradigm. Here, we summarize and highlight various bispecific immunotherapies under development in MM treatment, as well as the utility of combining them with current standard-of-care treatments and new strategies. With the advancement of novel combination treatment approaches, these bispecific molecules may lead the way to a cure for MM.<\/jats:p>","DOI":"10.3389\/fonc.2022.1032775","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T02:37:40Z","timestamp":1666060660000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":52,"title":["Bispecific antibodies in multiple myeloma treatment: A journey in progress"],"prefix":"10.3389","volume":"12","author":[{"given":"Shih-Feng","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Jang","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tzu","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosinol","year":"2012","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): A randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter imwg study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: Patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0184","article-title":"New strategies in multiple myeloma: Immunotherapy as a novel approach to treat patients with multiple myeloma","volume":"22","author":"Neri","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2067","article-title":"Bone marrow stromal cells create a permissive microenvironment for myeloma development: A new stromal role for wnt inhibitor Dkk1","volume":"72","author":"Fowler","year":"2012","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: Therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01822","article-title":"Osteoclast immunosuppressive effects in multiple myeloma: Role of programmed cell death ligand 1","volume":"9","author":"Tai","year":"2018","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1038\/bcj.2017.24","article-title":"Regulatory b cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu","volume":"7","author":"Zhang","year":"2017","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Gorgun","year":"2013","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/path.4860","article-title":"Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation","volume":"241","author":"De Beule","year":"2017","journal-title":"J Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"B22","article-title":"The role of interleukin-6 and interleukin-6\/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma","volume":"11","author":"Barille","year":"2000","journal-title":"Eur Cytokine Netw"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-015-9921-z","article-title":"Interleukin-10 induces both plasma cell proliferation and angiogenesis in multiple myeloma","volume":"21","author":"Alexandrakis","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0632","article-title":"Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment","volume":"10","author":"Hayashi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024372","article-title":"STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival","volume":"109","author":"Chatterjee","year":"2007","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JnJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","author":"Dahlen","year":"2018","journal-title":"Ther Adv Vaccines Immunother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific antibodies for multiple myeloma: A review of targets, drugs, clinical trials, and future directions","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":":1473","DOI":"10.3390\/cancers12061473","article-title":"BCMA-targeting therapy: Driving a new era of immunotherapy in multiple myeloma","volume":"12","author":"Cho","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a b-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":":28\u20139","DOI":"10.1182\/blood-2020-134063","article-title":"A phase 1 first in human (FIH) study of AMG 701, an anti-b-cell maturation antigen (BCMA) half-life extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule","volume":"136","author":"Harrison","year":"","journal-title":"J Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"Cars versus bites: A comparison between T cell-redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discovery"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.158.8.3965","article-title":"Biologic properties of a bispecific single-chain antibody directed against 17-1a (EPCAM) and CD3: Tumor cell-dependent T cell stimulation and cytotoxic activity","volume":"158","author":"Mack","year":"1997","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific antibody against b-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"key":"B38","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"Gamma-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum b-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-b-cell maturation antigen bite molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"LB","DOI":"10.1158\/1538-7445.am2018-lb-299","article-title":"Abstract lb-299: Cynomolgus monkey plasma cell gene signature to quantify the in vivo activity of a half-life extended anti-BCMA BiTE\u00ae for the treatment of multiple myeloma","volume":"78","author":"Goyos","year":"2018","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-4557","article-title":"Abstract 4557: BCMA-CD3 bispecific antibody pf-06863135: Preclinical rationale for therapeutic combinations","volume":"80","author":"Karwacz","year":"2020","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2021-150519","article-title":"Elranatamab (PF-06863135), a b-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-1","volume":"138","author":"Sebag","year":"2021","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"8014","DOI":"10.1200\/JCO.2022.40.16_suppl.8014","article-title":"Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1","volume":"40","author":"Jakubowiak","year":"2022","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1182\/blood-2019-126818","article-title":"Safety and preliminary clinical activity of REGN5458, an anti-BCMA x anti-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"134","author":"Cooper","year":"2019","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002736","article-title":"A BCMAxCD3 bispecific T cell\u2013engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells","volume":"5","author":"DiLillo","year":"2021","journal-title":"Blood Adv"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/01.Hs9.0000843648.44771.79","article-title":"S189: Early, deep, and durable responses, and low rates of crs with REGN5458, a BCMAxCD3 bispecific antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma","volume":"6","author":"Zonder","year":"2022","journal-title":"HemaSphere"},{"key":"B51","doi-asserted-by":"publisher","first-page":"8034+","DOI":"10.1200\/JCO.2018.36.15_suppl.8034","article-title":"Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma","volume":"36","author":"Buelow","year":"2018","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.69","article-title":"Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed\/refractory multiple myeloma","volume":"1","author":"Foureau","year":"2020","journal-title":"EJHaem"},{"key":"B53","doi-asserted-by":"publisher","first-page":"JCO2201504","DOI":"10.1200\/JCO.22.01504","article-title":"A phase i first-in-human study of ABBV-383, a b-cell maturation antigen x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","author":"D'Souza","year":"2022","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the b-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Interim results of a phase 1 multicenter trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1196\u2013206","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003342","article-title":"A t-cell\u2013redirecting bispecific g-protein\u2013coupled receptor class 5 member d x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1200\/JCO.2022.40.16_suppl.8015","article-title":"Efficacy and safety of talquetamab, a G protein-coupled receptor family c group 5 member d x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1","volume":"40","author":"Minnema","year":"2022","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/01.Hs9.0000843612.41180.42","article-title":"S180: RG6234, a novel GPRC5D T-cell engaging bispecific antibody, induces rapid responses in patients with relapsed\/refractory multiple myeloma: Preliminary results from a first-in-human trial","volume":"6","author":"Hasselbalch Riley","year":"2022","journal-title":"HemaSphere"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136985","article-title":"Initial clinical activity and safety of BFCR4350A, a FcRH5\/CD3 T-cell-engaging bispecific antibody, in relapsed\/refractory multiple myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s40425-019-0719-5","article-title":"Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8(+) T cells","volume":"7","author":"Mastelic-Gavillet","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.trecan.2019.11.005","article-title":"Targeting NAD(+) synthesis to potentiate CD38-based immunotherapy of multiple myeloma","volume":"6","author":"Kennedy","year":"2020","journal-title":"Trends Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004332","article-title":"The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: Therapeutic implications","volume":"136","author":"Ogiya","year":"2020","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1621","article-title":"BCMA-specific ADC MEDI2228 and daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression","volume":"27","author":"Xing","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"8044","DOI":"10.1200\/JCO.2021.39.15_suppl.8044","article-title":"Isb 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma","volume":"39","author":"Doucey","year":"2021","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/blood-2019-131540","article-title":"Preclinical characterization of an anti-CD38\/CD3 T cell-redirecting bispecific antibody","volume":"134","author":"He","year":"2019","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.242453","article-title":"BI38-3 is a novel CD38\/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma","volume":"106","author":"Fayon","year":"2021","journal-title":"Haematologica"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0519-4","article-title":"Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination","volume":"34","author":"Akhmetzyanova","year":"2020","journal-title":"Leukemia"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.2.388","article-title":"Serum syndecan-1: A new independent prognostic marker in multiple myeloma","volume":"95","author":"Seidel","year":"2000","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and\/or refractory multiple myeloma","volume":"19","author":"Jagannath","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4486.4486","article-title":"Indatuximab ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide: Clinical activity in patients with relapsed \/ refractory multiple myeloma","volume":"128","author":"Kelly","year":"2016","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41408-020-00378-z","article-title":"VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with imids or bortezomib in vitro and in vivo","volume":"10","author":"Yu","year":"2020","journal-title":"Blood Cancer J"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12631","article-title":"Immunotherapy based on bispecific T-cell engager with hIgG1 fc sequence as a new therapeutic strategy in multiple myeloma","volume":"106","author":"Zou","year":"2015","journal-title":"Cancer Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3109\/08923973.2016.1153110","article-title":"Anti-human CD138 monoclonal antibodies and their bispecific formats: Generation and characterization","volume":"38","author":"Chen","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzx043","article-title":"Trispecific antibodies for CD16a-directed NK cell engagement and dual-targeting of tumor cells","volume":"30","author":"Gantke","year":"2017","journal-title":"Protein Eng Des Sel"},{"key":"B82","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.1200\/JCO.2017.35.15_suppl.8045","article-title":"AFM26 is a novel, highly potent BCMA\/CD16a-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma","volume":"35","author":"Gantke","year":"2017","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000320","article-title":"BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma","volume":"43","author":"Wang","year":"2020","journal-title":"J Immunother"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1182\/blood-2019-128749","article-title":"CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma","volume":"134","author":"Watkins-Yoon","year":"2019","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B89","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/01.Hs9.0000843644.02496.66","article-title":"S188: Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed\/refractory multiple myeloma: Updated phase 1b results","volume":"6","author":"Rodriguez Otero","year":"2022","journal-title":"HemaSphere"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001792","article-title":"Bites better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e20014","article-title":"T-Cell redirected bispecific antibodies in relapsed and refractory multiple myeloma: A systematic review and meta-analysis","volume":"40","author":"Waqar","year":"2022","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5748","article-title":"Association of the COVID-19 outbreak with patient willingness to enroll in cancer clinical trials","volume":"7","author":"Fleury","year":"2021","journal-title":"JAMA Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956","article-title":"T-Cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1032775\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T15:11:46Z","timestamp":1678288306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1032775\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":96,"alternative-id":["10.3389\/fonc.2022.1032775"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1032775","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"article-number":"1032775"}}